Concepts (238)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Yellow fever virus | 2 | 2018 | 205 | 0.75 | Why? |
| Yellow Fever | 2 | 2018 | 231 | 0.69 | Why? |
| Air Travel | 1 | 2020 | 585 | 0.52 | Why? |
| Models, Theoretical | 11 | 2021 | 6659 | 0.46 | Why? |
| Epidemics | 8 | 2021 | 6407 | 0.45 | Why? |
| Disease Reservoirs | 3 | 2016 | 1672 | 0.42 | Why? |
| Epidemiological Monitoring | 3 | 2021 | 3493 | 0.42 | Why? |
| Camelus | 2 | 2019 | 1425 | 0.39 | Why? |
| Disease Outbreaks | 12 | 2020 | 27595 | 0.37 | Why? |
| Disease Susceptibility | 1 | 2021 | 4002 | 0.35 | Why? |
| Phylogeny | 3 | 2021 | 13341 | 0.31 | Why? |
| RNA Viruses | 1 | 2013 | 824 | 0.31 | Why? |
| Zoonoses | 3 | 2016 | 3034 | 0.30 | Why? |
| Evolution, Molecular | 3 | 2021 | 3691 | 0.30 | Why? |
| Communicable Diseases, Emerging | 5 | 2021 | 2523 | 0.29 | Why? |
| Risk | 1 | 2017 | 5288 | 0.28 | Why? |
| Bayes Theorem | 6 | 2021 | 3237 | 0.27 | Why? |
| Surge Capacity | 2 | 2021 | 894 | 0.25 | Why? |
| Basic Reproduction Number | 6 | 2021 | 2676 | 0.24 | Why? |
| Computational Biology | 2 | 2019 | 4514 | 0.24 | Why? |
| Immunity, Herd | 2 | 2020 | 1011 | 0.24 | Why? |
| Respiratory Tract Infections | 2 | 2013 | 6817 | 0.24 | Why? |
| Contact Tracing | 7 | 2021 | 8448 | 0.24 | Why? |
| Hemorrhagic Fever, Ebola | 3 | 2017 | 1475 | 0.22 | Why? |
| Age Factors | 3 | 2021 | 21039 | 0.22 | Why? |
| Communicable Disease Control | 10 | 2021 | 29620 | 0.22 | Why? |
| Epidemiologic Measurements | 1 | 2020 | 107 | 0.22 | Why? |
| Health Planning Guidelines | 1 | 2021 | 133 | 0.21 | Why? |
| Bacterial Vaccines | 1 | 2021 | 139 | 0.20 | Why? |
| Coronavirus Infections | 17 | 2020 | 253789 | 0.20 | Why? |
| Coronavirus | 3 | 2013 | 18339 | 0.20 | Why? |
| Phylogeography | 2 | 2021 | 824 | 0.20 | Why? |
| Middle East Respiratory Syndrome Coronavirus | 2 | 2019 | 8843 | 0.20 | Why? |
| Travel | 2 | 2020 | 7220 | 0.19 | Why? |
| Severe Acute Respiratory Syndrome | 8 | 2019 | 12361 | 0.19 | Why? |
| Virus Diseases | 3 | 2020 | 3779 | 0.19 | Why? |
| Management Information Systems | 1 | 2017 | 3 | 0.18 | Why? |
| Models, Statistical | 5 | 2020 | 5312 | 0.17 | Why? |
| Uruguay | 1 | 2017 | 169 | 0.17 | Why? |
| SARS Virus | 7 | 2019 | 13021 | 0.17 | Why? |
| Travel Medicine | 1 | 2020 | 335 | 0.17 | Why? |
| Health Policy | 2 | 2021 | 6242 | 0.17 | Why? |
| England | 4 | 2021 | 5116 | 0.16 | Why? |
| Dengue Vaccines | 1 | 2018 | 123 | 0.16 | Why? |
| Severe Dengue | 1 | 2018 | 135 | 0.16 | Why? |
| Humans | 61 | 2021 | 930598 | 0.16 | Why? |
| False Positive Reactions | 1 | 2021 | 1338 | 0.15 | Why? |
| Yellow Fever Vaccine | 1 | 2017 | 198 | 0.15 | Why? |
| Insect Vectors | 1 | 2017 | 227 | 0.15 | Why? |
| Viral Proteins | 1 | 2013 | 7370 | 0.14 | Why? |
| Child, Preschool | 8 | 2021 | 36283 | 0.14 | Why? |
| Programming Languages | 1 | 2014 | 51 | 0.14 | Why? |
| Entropy | 1 | 2014 | 52 | 0.14 | Why? |
| Genome, Viral | 5 | 2021 | 13157 | 0.14 | Why? |
| False Negative Reactions | 1 | 2021 | 1785 | 0.14 | Why? |
| Developing Countries | 2 | 2020 | 4283 | 0.14 | Why? |
| Pandemics | 19 | 2021 | 389249 | 0.14 | Why? |
| Child | 10 | 2021 | 70012 | 0.13 | Why? |
| Global Health | 5 | 2021 | 13911 | 0.13 | Why? |
| Argentina | 1 | 2017 | 1141 | 0.13 | Why? |
| Host-Pathogen Interactions | 1 | 2013 | 11041 | 0.12 | Why? |
| Vaccines, Attenuated | 1 | 2018 | 952 | 0.12 | Why? |
| Climate | 1 | 2018 | 557 | 0.12 | Why? |
| Seroepidemiologic Studies | 5 | 2021 | 10017 | 0.12 | Why? |
| Models, Biological | 4 | 2021 | 4907 | 0.12 | Why? |
| Adolescent | 10 | 2021 | 86841 | 0.12 | Why? |
| Age Distribution | 2 | 2021 | 3567 | 0.12 | Why? |
| Community Health Workers | 1 | 2017 | 468 | 0.12 | Why? |
| Infant | 6 | 2021 | 30274 | 0.12 | Why? |
| Environment | 1 | 2018 | 769 | 0.11 | Why? |
| Probability | 2 | 2014 | 923 | 0.11 | Why? |
| Brazil | 5 | 2021 | 12582 | 0.11 | Why? |
| Principal Component Analysis | 1 | 2013 | 689 | 0.11 | Why? |
| Algorithms | 4 | 2021 | 7346 | 0.11 | Why? |
| Dengue Virus | 1 | 2018 | 910 | 0.11 | Why? |
| Oncogene Proteins, Viral | 1 | 2010 | 36 | 0.11 | Why? |
| Infant, Newborn | 3 | 2021 | 23105 | 0.11 | Why? |
| Family Characteristics | 1 | 2021 | 2551 | 0.10 | Why? |
| Animals | 6 | 2019 | 78931 | 0.10 | Why? |
| Immunization, Secondary | 1 | 2018 | 1649 | 0.10 | Why? |
| Malaria | 1 | 2020 | 1097 | 0.10 | Why? |
| Africa | 1 | 2019 | 2986 | 0.10 | Why? |
| Prevalence | 4 | 2020 | 25773 | 0.10 | Why? |
| China | 5 | 2020 | 50654 | 0.10 | Why? |
| Pneumonia, Viral | 11 | 2020 | 243684 | 0.10 | Why? |
| Receptors, Cell Surface | 1 | 2013 | 586 | 0.10 | Why? |
| Incidence | 3 | 2021 | 25622 | 0.09 | Why? |
| Repressor Proteins | 1 | 2010 | 232 | 0.09 | Why? |
| Program Evaluation | 1 | 2017 | 1929 | 0.09 | Why? |
| Middle East | 1 | 2013 | 1418 | 0.09 | Why? |
| Singapore | 2 | 2019 | 3641 | 0.09 | Why? |
| Poverty | 1 | 2020 | 2302 | 0.09 | Why? |
| Genes, Viral | 1 | 2013 | 1428 | 0.09 | Why? |
| DNA-Binding Proteins | 1 | 2010 | 469 | 0.09 | Why? |
| Data Interpretation, Statistical | 1 | 2012 | 657 | 0.09 | Why? |
| Bacterial Infections | 1 | 2021 | 2229 | 0.08 | Why? |
| North America | 1 | 2012 | 1400 | 0.08 | Why? |
| Influenza, Human | 1 | 2012 | 10779 | 0.08 | Why? |
| Serologic Tests | 1 | 2021 | 4359 | 0.08 | Why? |
| World Health Organization | 3 | 2018 | 4213 | 0.08 | Why? |
| Adaptor Proteins, Signal Transducing | 1 | 2010 | 502 | 0.08 | Why? |
| Cluster Analysis | 2 | 2013 | 3001 | 0.08 | Why? |
| Europe | 5 | 2021 | 12702 | 0.08 | Why? |
| Genomics | 2 | 2021 | 3118 | 0.08 | Why? |
| Young Adult | 6 | 2021 | 93724 | 0.08 | Why? |
| Mortality | 2 | 2021 | 7132 | 0.08 | Why? |
| Software | 2 | 2019 | 2501 | 0.08 | Why? |
| United Kingdom | 3 | 2021 | 18046 | 0.08 | Why? |
| Health Services Needs and Demand | 1 | 2021 | 3419 | 0.08 | Why? |
| Germany | 2 | 2021 | 9196 | 0.08 | Why? |
| Africa, Western | 2 | 2017 | 363 | 0.07 | Why? |
| Databases, Factual | 1 | 2020 | 6248 | 0.07 | Why? |
| Aged, 80 and over | 4 | 2021 | 88759 | 0.07 | Why? |
| Adult | 11 | 2021 | 244371 | 0.07 | Why? |
| Seasons | 1 | 2018 | 4071 | 0.07 | Why? |
| Vaccination | 3 | 2021 | 19050 | 0.07 | Why? |
| Policy Making | 1 | 2012 | 829 | 0.07 | Why? |
| Sentinel Surveillance | 1 | 2012 | 1093 | 0.07 | Why? |
| Hospitals | 2 | 2021 | 11793 | 0.07 | Why? |
| Tuberculosis | 1 | 2020 | 2895 | 0.07 | Why? |
| Cross-Sectional Studies | 3 | 2021 | 53120 | 0.07 | Why? |
| Communicable Diseases | 1 | 2019 | 2148 | 0.07 | Why? |
| Aged | 10 | 2021 | 215776 | 0.06 | Why? |
| Binding Sites | 2 | 2013 | 6201 | 0.06 | Why? |
| Mass Screening | 2 | 2020 | 8005 | 0.06 | Why? |
| Italy | 4 | 2021 | 38444 | 0.06 | Why? |
| Phenotype | 1 | 2013 | 4037 | 0.06 | Why? |
| Spike Glycoprotein, Coronavirus | 3 | 2021 | 37182 | 0.06 | Why? |
| Vaccines | 1 | 2021 | 3692 | 0.06 | Why? |
| Time Factors | 3 | 2021 | 31397 | 0.06 | Why? |
| Disease Transmission, Infectious | 3 | 2020 | 9044 | 0.05 | Why? |
| Syria | 1 | 2021 | 170 | 0.05 | Why? |
| Hospitalization | 4 | 2020 | 54280 | 0.05 | Why? |
| Cohort Studies | 2 | 2021 | 36005 | 0.05 | Why? |
| Reverse Transcriptase Inhibitors | 1 | 2002 | 309 | 0.05 | Why? |
| Quarantine | 5 | 2021 | 18418 | 0.05 | Why? |
| Membrane Proteins | 1 | 2010 | 1733 | 0.05 | Why? |
| Survival Analysis | 1 | 2013 | 7592 | 0.05 | Why? |
| Middle Aged | 7 | 2021 | 270681 | 0.05 | Why? |
| Epidemiologic Methods | 1 | 2003 | 392 | 0.05 | Why? |
| Risk Assessment | 2 | 2013 | 25439 | 0.05 | Why? |
| Betacoronavirus | 8 | 2020 | 204454 | 0.05 | Why? |
| Computer Simulation | 1 | 2014 | 4982 | 0.05 | Why? |
| Spain | 1 | 2017 | 15545 | 0.05 | Why? |
| Angola | 1 | 2018 | 75 | 0.05 | Why? |
| Equipment and Supplies, Hospital | 1 | 2021 | 272 | 0.05 | Why? |
| Chiroptera | 1 | 2013 | 3530 | 0.05 | Why? |
| Mutation | 2 | 2021 | 12376 | 0.04 | Why? |
| Artificial Intelligence | 1 | 2013 | 3543 | 0.04 | Why? |
| HIV Infections | 2 | 2020 | 11620 | 0.04 | Why? |
| Models, Genetic | 1 | 2020 | 434 | 0.04 | Why? |
| Virulence Factors | 1 | 2020 | 338 | 0.04 | Why? |
| Viral Vaccines | 1 | 2019 | 7560 | 0.04 | Why? |
| Liberia | 1 | 2017 | 108 | 0.04 | Why? |
| State Medicine | 2 | 2021 | 2847 | 0.04 | Why? |
| Influenza A Virus, H1N1 Subtype | 1 | 2012 | 2984 | 0.04 | Why? |
| United States | 3 | 2021 | 46150 | 0.04 | Why? |
| Guinea | 1 | 2017 | 228 | 0.04 | Why? |
| Malawi | 1 | 2017 | 287 | 0.04 | Why? |
| Sierra Leone | 1 | 2017 | 267 | 0.04 | Why? |
| Public Health | 5 | 2021 | 16359 | 0.04 | Why? |
| Nucleocapsid | 1 | 2021 | 734 | 0.04 | Why? |
| Health Services Accessibility | 1 | 2020 | 10697 | 0.04 | Why? |
| Democratic Republic of the Congo | 1 | 2018 | 500 | 0.04 | Why? |
| Survival Rate | 3 | 2021 | 9206 | 0.04 | Why? |
| Asymptomatic Infections | 3 | 2020 | 7218 | 0.04 | Why? |
| Molecular Epidemiology | 1 | 2021 | 1638 | 0.04 | Why? |
| Mosquito Vectors | 1 | 2018 | 351 | 0.04 | Why? |
| Critical Care Nursing | 1 | 2021 | 469 | 0.04 | Why? |
| London | 1 | 2021 | 2166 | 0.04 | Why? |
| Public Health Practice | 1 | 2003 | 945 | 0.03 | Why? |
| Aedes | 1 | 2018 | 380 | 0.03 | Why? |
| Sweden | 1 | 2021 | 1969 | 0.03 | Why? |
| Spatio-Temporal Analysis | 1 | 2020 | 1182 | 0.03 | Why? |
| Denmark | 1 | 2021 | 2654 | 0.03 | Why? |
| Male | 10 | 2021 | 367725 | 0.03 | Why? |
| Focus Groups | 1 | 2017 | 811 | 0.03 | Why? |
| Patient Isolation | 2 | 2004 | 3182 | 0.03 | Why? |
| Cell Phone | 1 | 2021 | 750 | 0.03 | Why? |
| Hospital Bed Capacity | 1 | 2021 | 1300 | 0.03 | Why? |
| Mathematics | 2 | 2003 | 65 | 0.03 | Why? |
| RNA, Viral | 2 | 2019 | 32276 | 0.03 | Why? |
| Antibodies, Viral | 2 | 2021 | 51949 | 0.03 | Why? |
| Government | 1 | 2021 | 1453 | 0.03 | Why? |
| Discs Large Homolog 1 Protein | 1 | 2010 | 1 | 0.03 | Why? |
| Viral Load | 3 | 2021 | 15850 | 0.03 | Why? |
| Immunoglobulin G | 3 | 2021 | 21571 | 0.03 | Why? |
| Checklist | 1 | 2017 | 714 | 0.03 | Why? |
| PDZ Domains | 1 | 2010 | 46 | 0.03 | Why? |
| Hong Kong | 3 | 2004 | 3361 | 0.03 | Why? |
| Needs Assessment | 1 | 2020 | 2352 | 0.03 | Why? |
| Protein Binding | 2 | 2021 | 11430 | 0.03 | Why? |
| Urban Population | 1 | 2020 | 2000 | 0.02 | Why? |
| Female | 9 | 2021 | 380317 | 0.02 | Why? |
| Anti-HIV Agents | 1 | 2002 | 2209 | 0.02 | Why? |
| Virus Replication | 2 | 2018 | 14331 | 0.02 | Why? |
| Ebolavirus | 1 | 2016 | 834 | 0.02 | Why? |
| Cities | 1 | 2020 | 4937 | 0.02 | Why? |
| Interviews as Topic | 1 | 2017 | 1952 | 0.02 | Why? |
| Population Surveillance | 2 | 2021 | 4967 | 0.02 | Why? |
| Temperature | 1 | 2018 | 2305 | 0.02 | Why? |
| Risk Factors | 1 | 2017 | 71621 | 0.02 | Why? |
| Viral Envelope Proteins | 1 | 2020 | 3539 | 0.02 | Why? |
| Republic of Korea | 1 | 2020 | 5858 | 0.02 | Why? |
| HIV-1 | 1 | 2002 | 3365 | 0.02 | Why? |
| Magnetic Resonance Spectroscopy | 1 | 2010 | 881 | 0.02 | Why? |
| Qualitative Research | 1 | 2017 | 4337 | 0.02 | Why? |
| Saudi Arabia | 1 | 2016 | 4423 | 0.02 | Why? |
| Schools | 1 | 2021 | 4187 | 0.02 | Why? |
| France | 1 | 2021 | 12074 | 0.02 | Why? |
| Immunoglobulin M | 1 | 2021 | 9091 | 0.02 | Why? |
| Clinical Laboratory Techniques | 2 | 2020 | 23402 | 0.02 | Why? |
| Health Personnel | 3 | 2021 | 29646 | 0.02 | Why? |
| Viral Nonstructural Proteins | 1 | 2020 | 4810 | 0.01 | Why? |
| Elective Surgical Procedures | 1 | 2020 | 5338 | 0.01 | Why? |
| Kinetics | 1 | 2010 | 3238 | 0.01 | Why? |
| Stochastic Processes | 1 | 2003 | 369 | 0.01 | Why? |
| Patient Acceptance of Health Care | 1 | 2020 | 5002 | 0.01 | Why? |
| Likelihood Functions | 1 | 2003 | 719 | 0.01 | Why? |
| Social Isolation | 1 | 2020 | 5932 | 0.01 | Why? |
| Protein Conformation | 1 | 2010 | 4386 | 0.01 | Why? |
| Geography | 1 | 2006 | 1801 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2020 | 22971 | 0.01 | Why? |
| Sex Factors | 1 | 2016 | 11014 | 0.01 | Why? |
| CD4 Lymphocyte Count | 1 | 2002 | 1517 | 0.01 | Why? |
| History, 21st Century | 1 | 2004 | 1849 | 0.01 | Why? |
| Critical Care | 1 | 2020 | 14081 | 0.01 | Why? |
| Intensive Care Units | 1 | 2021 | 29594 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2021 | 48226 | 0.01 | Why? |
| Antibody Formation | 1 | 2006 | 4038 | 0.01 | Why? |
| Blood Donors | 1 | 2006 | 2956 | 0.01 | Why? |
| Treatment Outcome | 1 | 2018 | 51732 | 0.01 | Why? |
| Double-Blind Method | 1 | 2002 | 5988 | 0.01 | Why? |
| Retrospective Studies | 1 | 2021 | 105322 | 0.01 | Why? |
| Drug Therapy, Combination | 1 | 2002 | 7268 | 0.01 | Why? |
| Disease Progression | 1 | 2003 | 13580 | 0.00 | Why? |
| Cross Infection | 1 | 2003 | 8675 | 0.00 | Why? |
| Infection Control | 1 | 2003 | 23131 | 0.00 | Why? |